Compare Marriott International Inc (MAR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs ResMed Inc. — how do they compare? Marriott International Inc trades at $354.99 (market cap $91.14B), while ResMed Inc. trades at $225.38 (market cap $32.61B). The key difference: Marriott International Inc is far larger — about 2.8× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals.
| MAR | RMD | |
|---|---|---|
Market Cap | $91.14B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $293.73 |
52-Week Low | $259.04 | $182.82 |
Enterprise Value | $108.45B | $31.97B |
Dividend Yield | 0.84% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $356.31, up 2.26% today, with a bearish technical signal from moving averages. Recent Q2 2026 earnings beat estimates with EPS of $3.19 versus $3.08 expected, driven by strong fee revenue growth. The company raised its 2026 outlook, supported by a record pipeline and AI-powered booking tools, though valuation remains elevated with a P/E of 36.18.
Outlook is mixed: analyst consensus targets $387.31 (8.7% upside) with 44% buy ratings, but high debt and Middle East weakness pose risks. The stock offers growth via fee-based model and dividends, but requires monitoring of RevPAR trends and macroeconomic pressures for sustained gains.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
